High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 2, 2005, Pages 130-137

  Chaudhary, Uzair B ^a,b   Damon, Lloyd E ^a   Rugo, Hope S ^a   Linker, Charles A ^a   Navarro, Willis ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Germ cell cancer; High dose chemotherapy; Relapsed or refractory disease

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; ETOPOSIDE; THIOTEPA;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOXICITY; FEVER; FOLLOW UP; GERM CELL TUMOR; GLOMERULUS FILTRATION RATE; GRANULOCYTE; HUMAN; HUMAN CELL; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TOXICITY; LUNG HEMORRHAGE; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA; MUCOSA TOXICITY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RESPIRATORY FAILURE; SEPSIS; SKIN TOXICITY; THROMBOCYTE COUNT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CARBOPLATIN; ETOPOSIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS;

EID: 17044431738     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000144264.00518.47     Document Type: Article

References (27)

1. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435-1440.
2. Loehrer PJ Sr, Williams SD, Einhorn LH. Testicular cancer: the quest continues. J Natl Cancer Inst. 1988;80:1373-1382.
3. Loehrer PJ Sr, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol. 1986;4:528-536.
4. Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med. 1988 1;109:540-546.
5. Elias AD, Ayash LJ, Eder JP, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 1991;9:320-327.
6. Nichols CR, Anderson J, Lazarus HM, et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol. 1992;10:558-563.
7. Broun ER, Nichols CR, Kneebone P, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med. 1992;117:124-128.
8. Elias AD, Ayash LJ, Wheeler C, et al. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant. 1995;15:373-379.
9. Antman K, Eder JP, Elias A, et al. High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol. 1990;17:33-38.
10. Bateman JC. Chemotherapy of solid tumors with triethylene thiophosphoramide. N Engl J Med. 1955;252:879-887.
11. Wolff SN, Herzig RH, Fay JW, et al. High-dose N,N′,N″- triethylene-thiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol. 1990;17:2-6.
12. Rodenhuisuis S, Westermann A, Holtkamp MJ, et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol. 1996;14:1473-1483.
13. Small E, et al. Thiotepa, VP-16, and dose adjusted carboplatin (TVCA) with autologous bone marrow(ABM) or peripheral blood stem cell (PBSC) rescue for treatment of refractory germ cell tumors: efficacy and pharmacokinetic data. Proc ASCO. 1995.
14. Williams SF, Bitran JD, Kaminer L, et al. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol. 1987;5:260-265.
15. Broun ER, Nicholas CR, Gize G, et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer. 1997;79:1605-1610.
16. Janssen WE, Heimenz JW, Fields KK, et al. Blood and bone marrow hematopoietic stem cells for transplantation: a comparative review. Cancer Control. 1994;1:225-230.
17. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;11:1748-1756.
18. Van Echo DA, Egorin MJ, Aisner J. The pharmacology of carboplatin. Semin Oncol. 1989;16:1-6.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukemia after etoposide, cisplatin and bleomycin for germ cell tumors. Lancet. 1991;338:359-363.
21. Rick O, Bokemeyer C, Beyer J, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol. 2001;19:81-88.
22. Manandas RA, Saez RA, Epstein RB, et al. Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant. 1998;21:569-576.
23. Motzer RJ, Mazumdar M, Bajorin DF, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546-2552.
24. Rosti G, De Giorgi U, Salviani R, et al. Salvage treatment with high-dose chemotherapy followed by hematopoietic stem cell support in germ cell tumor patients. Biol Blood Marrow Transpl. 2002;8:71(Abstract 35).
25. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet. 1997;33:161-183.
26. Millward MJ, Webster LK, Toner GC, et al. Carboplatin dosing based on measurement of renal function-experience at the Peter MacCallum Cancer Institute. Aust N Z J Med. 1996;26:372-379.
27. Thomas H, Boddy AV, English MW, et al. Prospective validation of renal function-based carboplatin dosing in children with cancer: a United Kingdom Children Cancer Study Group Trial. J Clin Oncol. 2000;18:3614-3621.